ArriVent BioPharma to Present Phase 1 Data for ARR-217 at ESMO Congress 2026

ArriVent BioPharma, Inc. will present Phase 1 clinical trial data for its lead antibody-drug conjugate candidate, ARR-217, at the ESMO Congress 2026 in Madrid from October 23 to October 27, 2026. The results will be shared in a rapid oral presentation, and a virtual webinar is scheduled for October 26, 2026, to discuss the clinical data further. ARR-217 is being developed for gastrointestinal cancers, with exclusive rights held by ArriVent outside of Greater China through a collaboration with Lepu Biopharma Co., Ltd.